Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-338-5p mimic
- Development stage
- Preclinical
- Lead developer
- National Taiwan University
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-338-5p mimic is a synthetic RNA oligonucleotide designed to replicate the biological activity of the endogenous microRNA miR-338-5p. In esophageal squamous cell carcinoma (ESCC), miR-338-5p is frequently downregulated and acts as a tumor suppressor. The mimic functions by binding to the 3' untranslated region (UTR) of the Fermitin family member 2 (FERMT2) mRNA, leading to its degradation or translational repression. This downregulation of FERMT2 inhibits key oncogenic processes, including cell proliferation, migration, and colony formation. Furthermore, miR-338-5p mimic has been shown to enhance the sensitivity of ESCC cells to cisplatin-induced cytotoxicity, suggesting a potential role in overcoming chemoresistance.
- Other names
- microRNA-338-5p mimicmicroRNA338-5p mimicmicroRNA 338-5p mimichsa-miR-338-5p mimichsa-miR338-5p mimichsa-miR 338-5p mimic
02
Targets
SPINK1 (Serine peptidase inhibitor Kazal-type 1)FERMT2 (Fermitin family member 2)ETS1 (ETS proto-oncogene 1, transcription factor)
Beyond the preview
Go deeper on miR-338-5p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-338-5p mimic.